Trials / Unknown
UnknownNCT04437420
Preclinical Project on the Traitment of Acute Lymphoblastique Leukemia With NVP-BEP800, an Inhibitor of the Heat Shock Protein HSP90
- Status
- Unknown
- Phase
- —
- Study type
- Observational
- Enrollment
- 44 (estimated)
- Sponsor
- Centre Hospitalier Universitaire Dijon · Academic / Other
- Sex
- All
- Age
- 18 Years – 80 Years
- Healthy volunteers
- Not accepted
Summary
NVP-BEP800, a new HSP90 inhibitor, has particularly interesting therapeutic potential and represents hope in cancer pathologies. While it is currently being tested for solid cancers, no preclinical study has yet demonstrated its effectiveness in acute lymphoblastique leukemia (ALL). The investigators wish to study the effects of NVP-BEP800 on two different types of ALL (T and B-ALL).
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | injection of BEP 800 | injection of BEP 800 |
| OTHER | Control | no injection of BEP 800 |
Timeline
- Start date
- 2019-11-01
- Primary completion
- 2021-09-01
- Completion
- 2021-09-01
- First posted
- 2020-06-18
- Last updated
- 2020-06-23
Locations
1 site across 1 country: France
Source: ClinicalTrials.gov record NCT04437420. Inclusion in this directory is not an endorsement.